Strategy for the DKMA

The Danish Medicines Agency has formulated a strategy for 2022-26. The strategy emphasizes a vision of leading the way in national and international cooperation, and in the dialogue with citizens and society. Read more.

Go to theme

Vaccines and medicines against COVID-19

Read about the current studies and development of vaccines and medicines for treatment of COVID-19, and how medicines can be approved much quicker in extraordinary situations, if patient safety is sufficiently assured.

Go to theme

News and notifications

The Danish Medicines Agency suspends the Danish marketing authorisations of four generic medicines

13 December 2022

The European Commission has reached a decision in the case about the bioequivalence company Synchron Research, deciding that a number of generic medicines must be suspended in the EU counties where they are authorised. The Danish Medicines Agency therefore suspends the marketing authorisations of four medicines.

New executive order raises fees in the area of the Danish Medicines Agency

03 May 2022

Danish Medicines Agency presents new strategy

05 April 2022

Danish Medicines Agency closed over Christmas and New Year

15 December 2021